Aldeyra TherapeuticsALDX +1.95%29 Market Cap is $111.59 Mil as of Jun. 27, 2026. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,431 Biotechnology companies, Aldeyra Therapeutics ranks worse than 50.87% on this metric.
Aldeyra Therapeutics's quarterly market cap
declined
from Sep. 2025 ($314.05 Mil) to Dec. 2025 ($311.64 Mil) and
declined
from Dec. 2025 ($311.64 Mil) to Mar. 2026 ($101.94 Mil).
Aldeyra Therapeutics's annual market cap
increased
from Dec. 2023 ($207.78 Mil) to Dec. 2024 ($297.64 Mil) and
increased
from Dec. 2024 ($297.64 Mil) to Dec. 2025 ($311.64 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aldeyra Therapeutics's Enterprise Value for Today is $62.10 Mil.
Aldeyra Therapeutics (NAS:ALDX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aldeyra Therapeutics Market Cap Related Terms
Aldeyra Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Aldeyra Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aldeyra Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aldeyra Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aldeyra Therapeutics (ALDX) has a Market Cap of $111.59 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aldeyra Therapeutics and its competitors. According to the industry distribution chart, Aldeyra Therapeutics ranks #728 out of 1431 companies in the Biotechnology industry, placing it in the top 50.9%.
Is Aldeyra Therapeutics' Market Cap too high?
Aldeyra Therapeutics' current Market Cap is $111.59 Mil. The Biotechnology industry median Market Cap is 113.83. Aldeyra Therapeutics' value of $111.59 Mil is 2% below this industry median. Based on the distribution chart, Aldeyra Therapeutics ranks #728 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' Market Cap compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #728 out of 1431 companies for Market Cap. This places Aldeyra Therapeutics in the lower half of its industry. The industry median Market Cap is 113.83. Aldeyra Therapeutics' value of $111.59 Mil is 2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aldeyra Therapeutics's current Market Cap of $111.59 Mil is 2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aldeyra Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aldeyra Therapeutics's current Market Cap is $111.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current Market Cap of $111.59 Mil. The current Market Cap is $111.59 Mil and 2% below the Biotechnology industry median of 113.83. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current Market Cap is $111.59 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score
Get the complete analysis for ALDX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALDX has been successfully added to your 
